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Background 
There is a growing need for a non-invasive tool to identify patients at higher risk of 
hepatic decompensation among individuals with compensated non-alcoholic steatohepatitis 
(NASH) cirrhosis 
1
. HVPG has value in risk stratification
2
 and prediction of mortality among 
cirrhotics
3
 but has limitations of being invasive, costly, and requirement for expertise
4
. 
Enhanced Liver Fibrosis (ELF) score is based on circulating markers of hepatic matrix turnover 
and consists of hyaluronic acid, tissue inhibitor of metalloproteinases-1 (TIMP-1) and 





.  However, its utility as a prognostic biomarker among individuals with compensated 
cirrhosis due to NASH is unclear. This study evaluated the prognostic significance of ELF score 




This study was based on a 52-week phase 2 randomized controlled trial (NCT02462967), 
which evaluated belapectin (galectin receptor antagonist) for treating NASH cirrhosis 
7
. It 
consisted of 162 patients with biopsy-proven NASH compensated cirrhosis and portal 
hypertension. ELF (Advia Centaur Immunoassay), FIB-4 index, APRI, NAFLD fibrosis score, Child-
Turcotte-Pugh (CTP) and MELD scores were determined at baseline. The development of liver-
related events was defined as at least one of the following: development or progression of 
gastroesophageal varices, new-onset ascites, variceal hemorrhage, and hepatic 
encephalopathy, an increase of Child-Turcotte-Pugh (CTP) score ≥ 2 points from baseline or an 
increase in MELD score to >15. One subject dropped out of the study, and 161 were available 
for analysis. Using baseline ELF score, subjects were stratified as ELF ≥ 9.8 and ≥ 11.3 to assess 
risk (Kaplan-Meier curves) and clinical concordance (sensitivity, specificity, PPV, NPV, LR+, and 
LR-) of subsequent events. ELF cutoff values for stratification were based on existing literature
8
. 
Cox proportional hazard regressions were adjusted for age, sex, body mass index and type 2 
diabetes. C-statistics were used for discriminative capability of diagnostic tools.  
Results 
Supplemental Tables 1 and 2 describe the baseline characteristics according to presence 
of liver-related events and baseline ELF of 11.3 respectively. At 52 weeks, 33 (20%) patients 
developed liver-related events as follows: development or progression of varices, 17 (11%); 
decompensations, 13 (8%] or CTP≥2 or MELD>15, 3 (2%). Fourteen (9%) patients developed 
medium-large size varices and/or presence of red signs. As shown in Table 1 and Supplemental 
Figure 1A, there was a stepwise increase in the frequency of developing liver-related events 
among patients with ELF <9.8 (10.5%), 9.8 to 11.2 (16.9%), and ≥ 11.3 (32.7%).  Compared to 
ELF <9.8, patients with ELF of ≥ 11.3 had a significantly higher frequency of liver-related events 
(HR: 4.81, 95% CI: 1.54-15.05, P <0.01). Patients with ELF between 9.8 and 11.2 did not have a 
higher frequency of liver-related events compared to ELF <9.8 (HR 1.46, 95% CI: 0.45-4.65, 
P=0.08). We found a strong correlation between ELF and HVPG measurements at baseline 
(r=0.469, P<0.001) and end of study (r=0.657, P<0.001). 
The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) 
of ELF > 9.8 for predicting liver-related outcomes by 52 weeks was 87.9%, 26.6%, 23.6%, and 
89.5% respectively. The sensitivity, specificity, PPV, and NPV for ELF ≥ 11.3 for predicting liver-
related outcomes by 52 weeks was 51.5%, 72.7%, 32.7%, and 85.3%, respectively. 
Supplemental figure 1B shows ELF’s capability to discriminate patients with 1-year liver-related 
outcomes in comparison to NAFLD fibrosis score, FIB4, APRI, CTP and MELD scores. The area 
under the ROC curve was 0.67 (95% CI: 0.57-0.77) for baseline ELF and 0.68 (95% CI: 0.57-0.77) 
if a change in ELF over time was added to its baseline values (Supplemental figure 1C). 
 
Discussion 
This study demonstrates that ELF score strongly correlates with short-term risk of liver-related 
events, and a threshold of ≥11.3 is associated with a 5-fold higher risk of developing a liver-
related outcome.  Importantly, an ELF threshold <9.8 will be particularly accurate in ruling out 
the occurrence of liver-related outcomes in the short term (NPV 90%). ELF was superior to Fib4, 
MELD and CTP for predicting one-year risk of liver-related events. Correlation of ELF score with 
HVPG could explain its precise performance. Our study provides external validation for the ELF 
cut off scores used by Sanyal et al. for predicting liver-related complications among NASH 
patients with advanced fibrosis
8
.  
Our data is limited to small sample size with a short period of follow-up. Furthermore, our 
results might only apply to cirrhotic populations. If validated in large-scale studies with long-
term follow-up, ELF could be used to provide prognostic information and evaluate new 






























Abbreviations: ELF, Enhanced Liver Fibrosis; LR, likelihood ratio; CI, confidence interval. 
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